IOBT updates leadership as CAO departs and CFO takes accounting role

Rhea-AI Filing Summary

IO Biotech, Inc. reported that its Senior Vice President and Chief Accounting Officer, Brian Burkavage, has informed the company of his intent to resign effective December 12, 2025 to pursue another opportunity. The company stated that his resignation is not due to any dispute or disagreement with the company.

The company’s Chief Financial Officer, Amy Sullivan, has been designated as IO Biotech’s principal accounting officer, effective upon Mr. Burkavage’s departure. Her background is described in the company’s 2025 definitive proxy statement. IO Biotech noted that no new compensatory arrangements will be entered into with Ms. Sullivan in connection with her additional role.

false 0001865494 0001865494 2025-11-17 2025-11-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 17, 2025

IO BIOTECH, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware		001-41008		87-0909276
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Ole Maaløes Vej 3

DK-2200 Copenhagen N

Denmark

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: +45 7070 2980

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		IOBT		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Principal Accounting Officer

On November 17, 2025, Brian Burkavage informed IO Biotech, Inc. (the “Company”) of his intent to resign from his position as the Company’s Senior Vice President and Chief Accounting Officer, effective December 12, 2025. Mr. Burkavage plans to pursue another opportunity, and his resignation is not the result of any dispute or disagreement with the Company.

Appointment of Principal Accounting Officer

Amy Sullivan, the Company’s Chief Financial Officer, has been designated as the Company’s principal accounting officer, effective upon Mr. Burkavage’ departure. Ms. Sullivan’s biographical information is contained under the heading “Executive Officers” in the Company’s 2025 definitive proxy statement on Schedule 14A, which was filed with the U.S. Securities and Exchange Commission on April 25, 2025. No new compensatory arrangements will be entered into with Ms. Sullivan in connection with her service as principal accounting officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				IO BIOTECH, INC.
Date: November 21, 2025				By:		/s/ Mai-Britt Zocca, Ph.D.
				Name:		Mai-Britt Zocca, Ph.D.
				Title:		Chief Executive Officer

FAQ

What leadership change did IO Biotech (IOBT) announce in this 8-K?

IO Biotech announced that Brian Burkavage, its Senior Vice President and Chief Accounting Officer, intends to resign effective December 12, 2025, and that Amy Sullivan, the company’s Chief Financial Officer, will serve as the principal accounting officer following his departure.

Why is IO Biotech’s Chief Accounting Officer resigning?

The company stated that Brian Burkavage plans to pursue another opportunity and that his resignation is not the result of any dispute or disagreement with IO Biotech.

Who will serve as IO Biotech’s principal accounting officer after December 12, 2025?

Amy Sullivan, IO Biotech’s Chief Financial Officer, has been designated as the company’s principal accounting officer, effective upon Mr. Burkavage’s departure.

Will Amy Sullivan receive new compensation for becoming principal accounting officer at IO Biotech?

IO Biotech disclosed that no new compensatory arrangements will be entered into with Amy Sullivan in connection with her service as principal accounting officer.

Where can investors find more information about Amy Sullivan’s background at IO Biotech (IOBT)?

Her biographical information is contained under the heading “Executive Officers” in IO Biotech’s 2025 definitive proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission on April 25, 2025.

Did IO Biotech indicate any disagreement with the departing Chief Accounting Officer?

No. IO Biotech explicitly stated that Mr. Burkavage’s resignation is not the result of any dispute or disagreement with the company.